Optimal Timing of VT Ablation for Patients with ICD Therapies

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2020 Jul 11

PMID 32648057

Citations 2

Authors

Andrea Radinovic

Francesca Baratto

Paolo Della Bella

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Optimal timing for catheter ablation of ventricular tachycardia is an important yet unresolved subject. While it is clear that it is indicated with relatively advanced disease, it is still uncertain how early it should be recommended. In this review, we will focus on the status of timing of catheter ablation for VT in patients with ICD therapies.

Recent Findings: The latest expert consensus statement added a new timing indication for catheter ablation after the first episode of monomorphic VT, in patients with ischemic heart disease and an ICD. Early referral for catheter ablation reduces the number of VT recurrences; however, an impact on mortality has not been demonstrated yet. Guidelines and real-world data alike show an increasing trend to refer patients after the first VT episode in ICD patients. Randomized clinical trials powered to assess mortality are essential in order confirm the beneficial effects of an early strategy.

Citing Articles

Real-world evaluation of followup strategies after ICD therapies in patients with VT (REFINE-VT).

Tran P, Marshall L, Patchett I, Salim H, Yusuf S, Panikker S Br J Cardiol. 2022; 28(4):48.

PMID: 35747065 PMC: 9063697. DOI: 10.5837/bjc.2021.048.

Myocardial Scar Characterization and Future Ventricular Arrhythmia in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator.

Noordman A, Maass A, Groenveld H, Mulder B, Rienstra M, Blaauw Y Front Cardiovasc Med. 2021; 8:708406.

PMID: 34485409 PMC: 8415981. DOI: 10.3389/fcvm.2021.708406.

References

Cronin E, Bogun F, Maury P, Peichl P, Chen M, Namboodiri N . 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias: Executive summary. Heart Rhythm. 2019; 17(1):e155-e205. PMC: 8459311. DOI: 10.1016/j.hrthm.2019.03.014. View

Moss A, Schuger C, Beck C, Brown M, Cannom D, Daubert J . Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012; 367(24):2275-83. DOI: 10.1056/NEJMoa1211107. View

Noyes K, Corona E, Veazie P, Dick A, Zhao H, Moss A . Examination of the effect of implantable cardioverter-defibrillators on health-related quality of life: based on results from the Multicenter Automatic Defibrillator Trial-II. Am J Cardiovasc Drugs. 2009; 9(6):393-400. PMC: 4743243. DOI: 10.2165/11317980-000000000-00000. View

Vaseghi M, Barwad P, Malavassi Corrales F, Tandri H, Mathuria N, Shah R . Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias. J Am Coll Cardiol. 2017; 69(25):3070-3080. PMC: 6330109. DOI: 10.1016/j.jacc.2017.04.035. View

Vorperian V, Havighurst T, Miller S, January C . Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997; 30(3):791-8. DOI: 10.1016/s0735-1097(97)00220-9. View

Muser D, Liang J, Pathak R, Magnani S, Castro S, Hayashi T . Long-Term Outcomes of Catheter Ablation of Electrical Storm in Nonischemic Dilated Cardiomyopathy Compared With Ischemic Cardiomyopathy. JACC Clin Electrophysiol. 2018; 3(7):767-778. DOI: 10.1016/j.jacep.2017.01.020. View

Willems S, Tilz R, Steven D, Kaab S, Wegscheider K, Geller L . Preventive or Deferred Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy and Implantable Defibrillator (BERLIN VT): A Multicenter Randomized Trial. Circulation. 2020; 141(13):1057-1067. DOI: 10.1161/CIRCULATIONAHA.119.043400. View

Moss A, Greenberg H, Case R, Zareba W, Hall W, Brown M . Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004; 110(25):3760-5. DOI: 10.1161/01.CIR.0000150390.04704.B7. View

Gasparini M, Proclemer A, Klersy C, Kloppe A, Lunati M, Martinez Ferrer J . Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013; 309(18):1903-11. DOI: 10.1001/jama.2013.4598. View

10.

Tung R, Vaseghi M, Frankel D, Vergara P, Di Biase L, Nagashima K . Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015; 12(9):1997-2007. PMC: 4549209. DOI: 10.1016/j.hrthm.2015.05.036. View

11.

. International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group. J Am Coll Cardiol. 1984; 4(6):1148-63. DOI: 10.1016/s0735-1097(84)80133-3. View

12.

Frankel D, Mountantonakis S, Robinson M, Zado E, Callans D, Marchlinski F . Ventricular tachycardia ablation remains treatment of last resort in structural heart disease: argument for earlier intervention. J Cardiovasc Electrophysiol. 2011; 22(10):1123-8. DOI: 10.1111/j.1540-8167.2011.02081.x. View

13.

Dinov B, Arya A, Bertagnolli L, Schirripa V, Schoene K, Sommer P . Early referral for ablation of scar-related ventricular tachycardia is associated with improved acute and long-term outcomes: results from the Heart Center of Leipzig ventricular tachycardia registry. Circ Arrhythm Electrophysiol. 2014; 7(6):1144-51. DOI: 10.1161/CIRCEP.114.001953. View

14.

. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992; 327(4):227-33. DOI: 10.1056/NEJM199207233270403. View

15.

Muser D, Santangeli P, Castro S, Pathak R, Liang J, Hayashi T . Long-Term Outcome After Catheter Ablation of Ventricular Tachycardia in Patients With Nonischemic Dilated Cardiomyopathy. Circ Arrhythm Electrophysiol. 2016; 9(10). DOI: 10.1161/CIRCEP.116.004328. View

16.

Al-Khatib S, Daubert J, Anstrom K, Daoud E, Gonzalez M, Saba S . Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. J Cardiovasc Electrophysiol. 2014; 26(2):151-7. DOI: 10.1111/jce.12567. View

17.

Kuck K, Tilz R, Deneke T, Hoffmann B, Ventura R, Hansen P . Impact of Substrate Modification by Catheter Ablation on Implantable Cardioverter-Defibrillator Interventions in Patients With Unstable Ventricular Arrhythmias and Coronary Artery Disease: Results From the Multicenter Randomized Controlled SMS.... Circ Arrhythm Electrophysiol. 2017; 10(3). DOI: 10.1161/CIRCEP.116.004422. View

18.

Tanner H, Hindricks G, Volkmer M, Furniss S, Kuhlkamp V, Lacroix D . Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study. J Cardiovasc Electrophysiol. 2009; 21(1):47-53. DOI: 10.1111/j.1540-8167.2009.01563.x. View

19.

Kuck K, Schaumann A, Eckardt L, Willems S, Ventura R, Delacretaz E . Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010; 375(9708):31-40. DOI: 10.1016/S0140-6736(09)61755-4. View

20.

Romero J, Di Biase L, Diaz J, Quispe R, Du X, Briceno D . Early Versus Late Referral for Catheter Ablation of Ventricular Tachycardia in Patients With Structural Heart Disease: A Systematic Review and Meta-Analysis of Clinical Outcomes. JACC Clin Electrophysiol. 2018; 4(3):374-382. DOI: 10.1016/j.jacep.2017.12.008. View